Researchers at MIT have developed a groundbreaking approach to enhance the effectiveness of T cells in fighting cancer, potentially leading to more potent vaccines for both cancer and viral infections.

The technique involves using mRNA molecules to 'remodel' parts of the immune system. This process can slow tumor growth or even eradicate them, with promising results observed in mice models of various cancers.

In these studies, injections containing mRNA-encoded adjuvants enabled the immune system to combat tumors more effectively, even without a specific cancer vaccine. The adjuvant also bolstered the response to checkpoint blockade inhibitors, which are used to treat several types of cancer.

Additionally, this method significantly increased T-cell responses in mice vaccinated against viral infections like COVID-19 and influenza, generating reactions 10 to 15 times stronger than usual. The researchers aim to test their approach further in various animal models to develop applications for both cancer treatment and infectious disease prevention.